
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a clinical-stage biotechnology company with a promising pipeline of protein degradation therapies targeting a wide range of diseases. The company's focus on targeting disease-causing proteins through its PROTAC platform shows great potential for improving patients' lives. Despite the risks associated with clinical trials and competition in the market, Arvinas' strong financial position and partnerships with companies like Novartis demonstrate its potential to achieve success in the future and generate significant returns for investors.
Bears say
Arvinas is currently progressing its protein degradation therapies for various oncology and neurology-related diseases, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin Lymphoma, and ARV-102 for neurodegenerative disorders. However, the market may not fully credit the company until clinical benefits are demonstrated, despite ARV-102's compelling biomarker data, as its main competitor, Biogen, has not shown significant reductions in LRRK2 levels with their inhibitor. Arvinas' management remains confident in their product's potential, but a positive phase 2b result from Biogen could validate the LRRK2 pathway in the eyes of the market.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares